• Explore /
  • Poster
  • / Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).

Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).

Abstract Poster

Authors

Shilpa Gupta

Shilpa Gupta

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Shilpa Gupta , Yasuhisa Fujii , Michiel Simon Van Der Heijden , Andrew James Weickhardt , Nicholas D. James , Shahrokh F. Shariat , Jeff M. Michalski , Kentaro Imai , Xiao Fang , Ekta Kapadia , Neal D. Shore

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04241185

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS720)

DOI

10.1200/JCO.2024.42.4_suppl.TPS720

Abstract #

TPS720

Poster Bd #

M20

Abstract Disclosures

Similar Posters

First Author: Andrew James Weickhardt

First Author: Arjun Vasant Balar

First Author: Arlene O. Siefker-Radtke

First Author: Yung-Jue Bang